The effect of aspirin on niacin-induced cutaneous reactions.
BACKGROUND
Niacin (nicotinic acid) is one of the first-line agents recommended for the treatment of hyperlipidemia. Bothersome cutaneous reactions (flushing, feeling of warmth, itching, and tingling), however, often limit patient acceptability and tolerability. The National Cholesterol Education Program recommends giving aspirin or another nonsteroidal anti-inflammatory drug before administering niacin. Lack of scientific data supporting this recommendation, however, led to this randomized, double-blind, placebo-controlled trial to evaluate the efficacy of 80 mg of aspirin and 325 mg of aspirin in reducing these cutaneous reactions.


METHODS
Thirty-one healthy subjects were randomized into one of four groups. Each group completed four different treatment regimens (placebo-placebo; 80 mg of aspirin-500 mg of niacin; 325 mg of aspirin-500 mg of niacin; and placebo-500 mg of niacin). Subjects received one of each of the four treatment regimens on separate visits that were at least 24 hours apart. Intensity and tolerability of cutaneous reactions were evaluated by an intensity rating scale and a visual analog scale.


RESULTS
Results indicate that 325 mg of aspirin is significantly better than 80 mg of aspirin in decreasing intolerability to niacin. Aspirin reduced the incidence of warmth and flushing associated with niacin, but not the itching and tingling.


CONCLUSIONS
It appears from this pilot study that preceding niacin with 325 mg of aspirin will decrease the warmth and flushing associated with niacin.
Whelan
A M
AM
Department of Family Medicine, Medical University of South Carolina, Charleston.
Price
S O
SO
Fowler
S F
SF
Hainer
B L
BL
D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005483:Flushing / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D008297:Male; D009525:Niacin / Q000009:adverse effects* / Q000627:therapeutic use; D010865:Pilot Projects; D011537:Pruritus / Q000139:chemically induced / Q000517:prevention & control*
D009525:Niacin; D001241:Aspirin